News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Brane Discovery Srl Acquires ORL-1 Program from NiKem Research s.r.l.



6/4/2007 5:33:32 PM

MILAN, Italy, June 4th, 2007 - Brane Discovery Srl, a newly formed specialty pharmaceutical company focused on the development of novel CNS therapies, today announced the acquisition of a pre-clinical program targeting the Opioid Receptor Like-1 (ORL-1) from Nikem Research, who acquired ORL-1 from GlaxoSmithKline (GSK). The ORL-1 program originates in the 2003 research and development collaboration agreement GSK entered into with NiKem Research to discover novel modulators for the ORL-1 receptor. This antagonist program, which has already generated a preclinical candidate (BND-001), will now enter the broad preclinical CNS focused pipeline of Brane Discovery. Brane was spun out of NiKem Research in April 2007.

Read at PharmaLive


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES